Skip to main content

What Gilead's Quarter ended Sep 30, 2026 10-Q says: 6 signals

Gilead filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition announced, acquisition completed and bookings decline.

Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
16

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

10-Q · latest 10

What Gilead's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 6 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 6 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR

Showing 10 of 16 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Gilead earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
CMS Maximum Fair Price sets $1.5B revenue headwind for 2028CMS selected Biktarvy for the Maximum Fair Price determination process, establishing a price of $2,600 per 30-day supply (a 38% discount from Medicare list price). Management expects this to create a net revenue decline of approximately $1.5 billion in 2028 across Medicare, Medicaid, 340B, and commercial spillover channels.
Product sales rise 13% to $8.3B, base up 16%Third quarter total product sales rose 13% year-over-year to $8.3 billion, driven by strong performance across HIV treatment and prevention, Trodelvy, and Livdelzi. Excluding Veklury, base product sales reached $8.2 billion, up 16% year-over-year, marking the company's highest base growth rate since 2015. Demonstrates massive operational cash generation and expanding commercial budget capacity...
Cell Therapy sales fall 18% due to competitive headwindsThird-quarter Cell Therapy revenue dropped 18% year-over-year to $355 million due to intensifying competitive pressure in the CAR-T space. The company is seeking to offset this decline by launching anito-cel in multiple myeloma, with an upcoming PDUFA date on December 23.
Preactivation of 80% Authorized Treatment Centers for anito-cel launchAhead of anito-cel's December 23 PDUFA date in multiple myeloma, Kite is initiating preactivation programs targeting 80% of Authorized Treatment Centers within 6 months. Commercial and access teams are also targeting 90% payer coverage within 12 months to drive brand leadership within 18 months of approval.
Partnership with Lakefront advances bispecific T-cell engager therapiesGilead is advancing an early-stage portfolio of bispecific T-cell engagers acquired through Ouro Medicines in partnership with Lakefront. The lead candidate, gamgertamig (BCMAxCD3), demonstrated robust activity in Phase I trials across autoimmune conditions and is on track for Phase III trials next year.
Clinical hold on oral 3107 due to unexpected metabolitesGilead's once-monthly oral HIV prodrug compound GS-3107 was placed on a clinical hold after unexpected metabolite impacts were detected. Management is currently resolving the hold while simultaneously progressing backup research molecules for monthly oral treatment.

Signal API · MCP

Track Gilead with the Signal API

One POST /v1/companies/enrich call with gilead.com returns Gilead 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Gilead 10-Q

When did Gilead file its latest 10-Q?
Gilead filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Aug 6, 2026.
What did Gilead disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: Gilead completed acquisitions of Arcellx for $7.0B, Tubulis for $3.1B, and Ouro Medicines
What did Gilead say on its recent earnings calls?
Q3 FY2026: CMS Maximum Fair Price sets $1.5B revenue headwind for 2028 (dated Oct 29, 2026).
Where can I read Gilead's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/gild-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →